Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Medtronic

Executive Summary

Medtronic: SynchroMed pump using Ciba-Geigy's Lioresal (baclofen) Intrathecal receives FDA clearance for Treatment Protocol in the control of spasticity of cerebral origin, including spastic cerebral palsy and severe spasticity related to head trauma. The drug-device combo has been marketed since October 1992 for spasticity in patients with spinal cord lesions or multiple sclerosis. Medtronic estimates there are 35,000 cerebral palsy patients in the U.S. who might benefit from the therapy. Under the Treatment Protocol, Medtronic charges for the SynchroMed pump, which lists for about $7,000, but will provide the drug free...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel